Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189]
Vaccine X
.
2023 Aug:14:100307.
doi: 10.1016/j.jvacx.2023.100307.
Epub 2023 Apr 28.
Authors
Xavier Sáez-Llorens
1
,
Claudio Lanata
2
,
Elaine Aranguren
1
,
Carlos R Celis
3
,
Rubelio Cornejo
2
,
Rodrigo DeAntonio
1
,
Lucie Ecker
2
,
Diegi Garrido
1
,
Ana I Gil
3
,
Marina Gonzales
4
,
Morgan Hess-Holtz
1
,
Geert Leroux-Roels
5
,
Helga Junker
6
,
Sarah-Katharina Kays
5
,
Sven D Koch
4
,
Sandra Lazzaro
4
,
Philipp Mann
6
,
Gianluca Quintini
4
,
Barkha Srivastava
4
,
Dominik Vahrenhorst
4
,
Philipp von Eisenhart-Rothe
4
,
Olaf-Oliver Wolz
4
,
Lidia Oostvogels
6
Affiliations
1
Cevaxin, The Panama Clinic, Panama City, Panama.
2
Instituto de Investigación Nutricional, Lima, Peru.
3
Instituto de Investigación Nutricional, La Molina, Peru.
4
CureVac AG, Tübingen, Germany.
5
Ghent University Hospital, Ghent, Belgium.
6
CureVac AG, Frankfurt, Germany.
PMID:
37131960
PMCID:
PMC10139920
DOI:
10.1016/j.jvacx.2023.100307
Abstract
[This corrects the article DOI: 10.1016/j.jvacx.2022.100189.].
© 2023 The Author(s).
Publication types
Published Erratum